Cargando…
Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry
Prospective data are lacking concerning the effect of reduced mycophenolic acid (MPA) dosing on efficacy and the influence of concomitant tacrolimus exposure. The Mycophenolic Renal Transplant (MORE) Registry is a prospective, observational study of de novo kidney transplant patients receiving MPA t...
Autores principales: | Langone, Anthony, Doria, Cataldo, Greenstein, Stuart, Narayanan, Mohanram, Ueda, Kimi, Sankari, Bashir, Pankewycz, Oleh, Shihab, Fuad, Chan, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593178/ https://www.ncbi.nlm.nih.gov/pubmed/22861144 http://dx.doi.org/10.1111/j.1399-0012.2012.01694.x |
Ejemplares similares
-
Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry
por: Doria, Cataldo, et al.
Publicado: (2012) -
Mycophenolate-mofetil/prednisone/tacrolimus: Infections: case report
Publicado: (2020) -
Mycophenolate mofetil/tacrolimus: Cutaneous leishmaniasis: case report
Publicado: (2021) -
Mycophenolate-mofetil/tacrolimus: COVID-19: case report
Publicado: (2022) -
Mycophenolate/prednisone/tacrolimus: Guillain-Barre syndrome: case report
Publicado: (2020)